DarioHealth Prices $23.5M Direct Offering At-The-Market, Board Member Participates
DRIO is trading near its 52-week low of $5.845 (14% above the low).
Summary
DarioHealth priced a $23.5 million registered direct offering of 3.45 million shares at $6.80, at-the-market under Nasdaq rules. A board member bought 14,430 shares at $6.93. The raise follows a going-concern warning in May and a $20 million ATM program established in March—this new offering adds significant dilution on top of existing capital needs. With a market cap around $51 million, the $23.5 million raise is highly dilutive, though the at-market pricing and insider participation suggest some institutional support. Proceeds are for working capital, investments, and acquisitions, but the company's cash burn and declining revenue raise questions about how long this funding will last.
At the time of this announcement, DRIO was trading at $6.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.2M. The 52-week trading range was $5.84 to $17.74. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.